Denali Therapeutics (NASDAQ:DNLI) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Denali Therapeutics (NASDAQ:DNLI) from a hold rating to a sell rating in a research note published on Saturday,Wall Street Zen reports.

A number of other analysts have also recently weighed in on the stock. Sanford C. Bernstein reissued a “hold” rating on shares of Denali Therapeutics in a research note on Monday, June 22nd. Stifel Nicolaus set a $41.00 price objective on Denali Therapeutics in a report on Monday, June 22nd. Morgan Stanley lifted their price objective on Denali Therapeutics from $35.00 to $36.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. JPMorgan Chase & Co. assumed coverage on Denali Therapeutics in a research note on Monday, July 13th. They issued an “overweight” rating and a $29.00 price objective on the stock. Finally, B. Riley Financial increased their target price on Denali Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, August 25th. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $35.85.

Denali Therapeutics Price Performance

Shares of DNLI stock opened at $22.28 on Friday. The stock has a market cap of $3.56 billion, a P/E ratio of -7.85 and a beta of 1.01. Denali Therapeutics has a one year low of $12.58 and a one year high of $27.30. The stock has a fifty day moving average price of $24.36 and a 200 day moving average price of $21.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The business had revenue of $3.60 million for the quarter, compared to analysts’ expectations of $2.15 million. During the same quarter in the prior year, the company earned ($0.72) EPS. Analysts predict that Denali Therapeutics will post -2.67 earnings per share for the current year.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total value of $71,624.99. Following the transaction, the insider owned 281,763 shares of the company’s stock, valued at approximately $7,063,798.41. The trade was a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 9.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Denali Therapeutics in the 2nd quarter valued at about $26,000. Headlands Technologies LLC bought a new stake in shares of Denali Therapeutics during the second quarter valued at approximately $26,000. Global Retirement Partners LLC bought a new stake in shares of Denali Therapeutics during the second quarter valued at approximately $28,000. Johnson Financial Group Inc. acquired a new stake in shares of Denali Therapeutics in the third quarter valued at approximately $29,000. Finally, State of Wyoming acquired a new stake in shares of Denali Therapeutics in the second quarter valued at approximately $29,000. 92.92% of the stock is owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.